Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4742521 | 0.81 | POLB (0.38) | ALDH1A1TSHRNFKB1CYP2C19DPP4 | |
| SCHEMBL4742170 | 0.81 | CYP1A2 (0.41) | SMN1; SMN2ALDH1A1TSHRCYP2C19 | |
| SCHEMBL10203868 | 0.80 | LMNA (0.39) | LMNASMN1; SMN2ALDH1A1TSHRNFKB1 | |
| SCHEMBL4730461 | 0.77 | LMNA (0.37) | LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL4741427 | 0.76 | HTT (0.38) | LMNASMN1; SMN2ALDH1A1CYP2C19POLB | |
| SCHEMBL16563021 | 0.75 | DPP4 (0.35) | TSHRNFKB1CYP2C19DPP4 | |
| SCHEMBL16980483 | 0.75 | DPP4 (0.35) | TSHRNFKB1CYP2C19DPP4 | |
| SCHEMBL4743137 | 0.75 | DPP4 (0.35) | TSHRNFKB1CYP2C19DPP4 | |
| SCHEMBL4743121 | 0.75 | CYP1A2 (0.41) | SMN1; SMN2ALDH1A1TSHRCYP2C19DPP4 | |
| SCHEMBL16980481 | 0.74 | GRIN2B (0.46) | SMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120114600-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS | THERAVANCE, INC. (US) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120114600-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, ZC3HAV1 | LMNA 3671/4885SMN1; SMN2 4692/4885ALDH1A1 1042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.